Abstract

The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an *in vitro* NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.

[Figure 1]